Clinical Trial Update: GW572016 For Treatment Of Refractory Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of GW572016 (lapatinib) for refractory metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tykerb (lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 2 | Status: COMPLETED